Rheumatoid arthritis: The two faces of Rsk2 in hyperplastic disease

Christopher Buckley; Jane Falconer

doi:10.1038/nrrheum.2015.1

Rheumatoid arthritis: The two faces of Rsk2 in hyperplastic disease

Christopher Buckley, Jane Falconer

Inflammation and Ageing

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

15 Downloads (Pure)

Abstract

Given the established role of 90 kDa ribosomal S6 kinases (Rsk) in oncogenesis, and the promise of new Rsk-blocking cancer treatments, it is perhaps surprising that Rsk2-mediated inhibition of hyperplasia has now been demonstrated to occur in the arthritic synovium. Does this functional duality make Rsk2 a risky target for the treatment of rheumatoid arthritis?

Original language	English
Pages (from-to)	203-205
Number of pages	3
Journal	Nature Reviews Rheumatology
Volume	11
Issue number	4
Early online date	27 Jan 2015
DOIs	https://doi.org/10.1038/nrrheum.2015.1
Publication status	Published - Apr 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrrheum.2015.1

http://www.nature.com/nrrheum/journal/v11/n4/full/nrrheum.2015.1.html

Cite this

@article{4a1dd36d01c94e9db5450b09e20d24a7,

title = "Rheumatoid arthritis: The two faces of Rsk2 in hyperplastic disease",

abstract = "Given the established role of 90 kDa ribosomal S6 kinases (Rsk) in oncogenesis, and the promise of new Rsk-blocking cancer treatments, it is perhaps surprising that Rsk2-mediated inhibition of hyperplasia has now been demonstrated to occur in the arthritic synovium. Does this functional duality make Rsk2 a risky target for the treatment of rheumatoid arthritis?",

author = "Christopher Buckley and Jane Falconer",

year = "2015",

month = apr,

doi = "10.1038/nrrheum.2015.1",

language = "English",

volume = "11",

pages = "203--205",

journal = "Nature Reviews Rheumatology",

issn = "1759-4790",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Rheumatoid arthritis

T2 - The two faces of Rsk2 in hyperplastic disease

AU - Buckley, Christopher

AU - Falconer, Jane

PY - 2015/4

Y1 - 2015/4

N2 - Given the established role of 90 kDa ribosomal S6 kinases (Rsk) in oncogenesis, and the promise of new Rsk-blocking cancer treatments, it is perhaps surprising that Rsk2-mediated inhibition of hyperplasia has now been demonstrated to occur in the arthritic synovium. Does this functional duality make Rsk2 a risky target for the treatment of rheumatoid arthritis?

AB - Given the established role of 90 kDa ribosomal S6 kinases (Rsk) in oncogenesis, and the promise of new Rsk-blocking cancer treatments, it is perhaps surprising that Rsk2-mediated inhibition of hyperplasia has now been demonstrated to occur in the arthritic synovium. Does this functional duality make Rsk2 a risky target for the treatment of rheumatoid arthritis?

U2 - 10.1038/nrrheum.2015.1

DO - 10.1038/nrrheum.2015.1

M3 - Article

SN - 1759-4790

VL - 11

SP - 203

EP - 205

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

IS - 4

ER -

Rheumatoid arthritis: The two faces of Rsk2 in hyperplastic disease

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this